title: Vaccinology capacity building in Europe for innovative platforms serving emerging markets.
abstract: The 2012 Terrapinn World Vaccine Congress held from 16 to 18 October in Lyon addressed in a dedicated session the transfer of innovative vaccine technologies from Europe to emerging markets. Past and recent transfers and experiences from Europe's public domain were summarized by the Netherlands' National Institute for Public Health and the Environment (RIVM) in Bilthoven. The role of capacity building through training courses for developing country partners was highlighted in several recent technology transfer programs developed in collaboration with the World Health Organisation (WHO). In another stream of the Congress, a case of human vaccine technology transfer from Europe's private sector to an emerging economy recipient in India was presented. The continuing globalization of vaccinology is further illustrated by the recent acquisition in 2012 of the Netherlands' public vaccine manufacturing capacity in Bilthoven by the Serum Institute of India Ltd, an emerging vaccine manufacturer. In a parallel development, the Netherlands' government decided to transform RIVM's vaccinology research and development capacity into a new not-for-profit entity: "the Institute for Translational Vaccinology" (see citation 1 in Note section for web address). Under a public private partnership structure, InTraVacc's mission will include the fostering of global health through international partnerships in innovative vaccinology. Projected activities will include training courses and curricula, capitalizing on various currently established platform technologies and the legacy of previous "producer -producer" collaborations between the RIVM and emerging manufacturers over the past 40 y. It is suggested to consider this as a basis for a common initiative from Europe to develop and implement a practical vaccinology course for emerging countries with particular focus to the African region.
authors.affiliation: Knowledge Transfer and Partnerships (KTP); Vaccinology Unit; National Institute for Public Health and the Environment (RIVM); Bilthoven, the Netherlands.
authors.forename: Jan
authors.initials: J
authors.lastname: Hendriks
authors.forename: Marit
authors.initials: M
authors.lastname: Holleman
authors.forename: Ahd
authors.initials: A
authors.lastname: Hamidi
authors.forename: Michel
authors.initials: M
authors.lastname: Beurret
authors.forename: Claire
authors.initials: C
authors.lastname: Boog
mesh_terms: D057191:Capacity Building / Q000191:economics / Q000458:organization & administration*; D003906:Developing Countries; D055808:Drug Discovery / Q000191:economics / Q000379:methods*; D005060:Europe; D006801:Humans; D018581:Technology Transfer; D013678:Technology, Pharmaceutical / Q000191:economics / Q000379:methods*; D014612:Vaccines / Q000191:economics / Q000302:isolation & purification*
chemical_list: D014612:Vaccines
keywords: Developing Country Vaccine Manufacturers’ Network (DCVMN); global health; technology transfer; training; translational vaccinology; vaccinology capacity building
references.citation: Vaccine. 2012 Jul 13;30(33):4897-906
references.pmid: 22683521
references.citation: PLoS Negl Trop Dis. 2011 Nov;5(11):e1300
references.pmid: 22140586
references.citation: Vaccine. 2008 Mar 20;26(13):1611-5
references.pmid: 18294742
references.citation: Vaccine. 2012 Sep 28;30(44):6230-40
references.pmid: 22902679
references.citation: Vaccine. 2009 Jan 29;27(5):631-2
references.pmid: 19022316
references.citation: Vaccine. 2011 Sep 22;29(41):7188-96
references.pmid: 21651934
references.citation: Biologicals. 2006 Jun;34(2):155-8
references.pmid: 16650773
references.citation: Vaccine. 2011 Jul 1;29 Suppl 1:A8-11
references.pmid: 21684431